# NSE/Alb as a Prognostic Biomarker for Lung Cancer

> **NCT03724604** · — · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 202 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DIAGNOSTIC_TEST:** Neuron-Specific Enolase to Albumin Ratio

## Key facts

- **NCT ID:** NCT03724604
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-06-30
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2019-05-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724604, "NSE/Alb as a Prognostic Biomarker for Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03724604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*